Source comparison
BPC-157 Dosing: Research Protocols Comparison
Standard Soft Tissue Protocol 250mcg Twice daily Subcutaneous (near injury) 4–6 weeks Most commonly referenced in research communities. Balances dosing convenience with sustained tissue exposure High-Dose Acute Injury Protocol 500mcg 2–4 weeks Used for acute i
This comparison does not assign a generated winner or score.
- Standard Soft Tissue Protocol
- 250mcg
- Twice daily
- Subcutaneous (near injury)
- 4–6 weeks
- Most commonly referenced in research communities. Balances dosing convenience with sustained tissue exposure
- High-Dose Acute Injury Protocol
- 500mcg
- 2–4 weeks
- Used for acute injuries requiring rapid intervention. Lacks long-term safety data at this dose
- Systemic Maintenance Protocol
- 200mcg
- Once daily
- Subcutaneous (abdomen)
- 6–8 weeks
- Lower dose for systemic anti-inflammatory effects rather than targeted repair. Less evidence supporting efficacy
- Oral Capsule Protocol
- 500–1,000mcg
- Oral (enteric-coated)
- 4–8 weeks
- Convenience-driven but bioavailability is significantly lower. Appropriate only for mild systemic support, not localized repair